H Lundbeck A/S (HLUN-A) - Total Assets
Based on the latest financial reports, H Lundbeck A/S (HLUN-A) holds total assets worth Dkr54.01 Billion DKK (≈ $8.45 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of H Lundbeck A/S to assess the company's total reinvestment commitment from operating cash flow.
H Lundbeck A/S - Total Assets Trend (2004–2025)
This chart illustrates how H Lundbeck A/S's total assets have evolved over time, based on quarterly financial data. Check H Lundbeck A/S cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
H Lundbeck A/S - Asset Composition Analysis
Current Asset Composition (December 2025)
H Lundbeck A/S's total assets of Dkr54.01 Billion consist of 23.7% current assets and 76.3% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 6.4% |
| Accounts Receivable | Dkr4.55 Billion | 8.4% |
| Inventory | Dkr4.47 Billion | 8.3% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr28.77 Billion | 53.3% |
| Goodwill | Dkr7.01 Billion | 13.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how H Lundbeck A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see H Lundbeck A/S (HLUN-A) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: H Lundbeck A/S's current assets represent 23.7% of total assets in 2025, a decrease from 51.7% in 2004.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2025, down from 25.2% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 14.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 53.3% of total assets.
H Lundbeck A/S Competitors by Total Assets
Key competitors of H Lundbeck A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
H Lundbeck A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.44 | 1.52 | 1.02 |
| Quick Ratio | 0.94 | 1.05 | 0.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr3.93 Billion | Dkr4.43 Billion | Dkr143.00 Million |
H Lundbeck A/S - Advanced Valuation Insights
This section examines the relationship between H Lundbeck A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.41 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -5.2% |
| Total Assets | Dkr54.01 Billion |
| Market Capitalization | $1.12 Billion USD |
Valuation Analysis
Below Book Valuation: The market values H Lundbeck A/S's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: H Lundbeck A/S's assets decreased by 5.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for H Lundbeck A/S (2004–2025)
The table below shows the annual total assets of H Lundbeck A/S from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr54.01 Billion ≈ $8.45 Billion |
-5.20% |
| 2024-12-31 | Dkr56.98 Billion ≈ $8.91 Billion |
+52.31% |
| 2023-12-31 | Dkr37.41 Billion ≈ $5.85 Billion |
-0.12% |
| 2022-12-31 | Dkr37.45 Billion ≈ $5.86 Billion |
+8.08% |
| 2021-12-31 | Dkr34.65 Billion ≈ $5.42 Billion |
-3.82% |
| 2020-12-31 | Dkr36.03 Billion ≈ $5.64 Billion |
+0.76% |
| 2019-12-31 | Dkr35.76 Billion ≈ $5.59 Billion |
+55.39% |
| 2018-12-31 | Dkr23.01 Billion ≈ $3.60 Billion |
+16.48% |
| 2017-12-31 | Dkr19.76 Billion ≈ $3.09 Billion |
-2.25% |
| 2016-12-31 | Dkr20.21 Billion ≈ $3.16 Billion |
-5.23% |
| 2015-12-31 | Dkr21.32 Billion ≈ $3.34 Billion |
-16.82% |
| 2014-12-31 | Dkr25.64 Billion ≈ $4.01 Billion |
+8.41% |
| 2013-12-31 | Dkr23.65 Billion ≈ $3.70 Billion |
+9.67% |
| 2012-12-31 | Dkr21.56 Billion ≈ $3.37 Billion |
+5.01% |
| 2011-12-31 | Dkr20.53 Billion ≈ $3.21 Billion |
+14.05% |
| 2010-12-31 | Dkr18.00 Billion ≈ $2.82 Billion |
+5.13% |
| 2009-12-31 | Dkr17.13 Billion ≈ $2.68 Billion |
+35.86% |
| 2008-12-31 | Dkr12.61 Billion ≈ $1.97 Billion |
+2.28% |
| 2007-12-31 | Dkr12.33 Billion ≈ $1.93 Billion |
+5.98% |
| 2006-12-31 | Dkr11.63 Billion ≈ $1.82 Billion |
+0.02% |
| 2005-12-31 | Dkr11.63 Billion ≈ $1.82 Billion |
+1.04% |
| 2004-12-31 | Dkr11.51 Billion ≈ $1.80 Billion |
-- |
About H Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more